id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2016-E-2181-0006,FDA,FDA-2016-E-2181,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2018-07-29T04:00:00Z,2018,7,2018-07-29T04:00:00Z,,2018-07-29T05:52:51Z,,0,0,090000648357ae98
FDA-2016-E-2181-0005,FDA,FDA-2016-E-2181,"Determination of Regulatory Review Period for Purposes of Patent
Extension; XURIDEN",Notice,Determinations,2017-11-29T05:00:00Z,2017,11,2017-11-29T05:00:00Z,2018-01-30T04:59:59Z,2017-11-29T16:32:21Z,2017-25770,0,0,0900006482cbbcc8
FDA-2016-E-2181-0004,FDA,FDA-2016-E-2181,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2017-08-21T04:00:00Z,2017,8,2017-08-21T04:00:00Z,,2017-08-21T16:42:47Z,,0,0,0900006482a8c9ca
FDA-2016-E-2181-0003,FDA,FDA-2016-E-2181,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2016-08-26T04:00:00Z,2016,8,2016-08-26T04:00:00Z,,2016-08-26T14:02:13Z,,0,0,090000648219ff67
FDA-2016-E-2181-0002,FDA,FDA-2016-E-2181,Letter from U.S. Patent and Trademark Office,Other,Letter(s),2016-07-22T04:00:00Z,2016,7,2016-07-22T04:00:00Z,,2016-07-22T18:09:57Z,,0,0,09000064820f1e23
FDA-2016-E-2181-0001,FDA,FDA-2016-E-2181,Wellstat Therapeutics Corporation - Patent Extension Application,Other,Application,2016-07-22T04:00:00Z,2016,7,2016-07-22T04:00:00Z,,2016-07-22T18:09:52Z,,0,0,09000064820f1e21